Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Susan
S. Schiffman & Kristina
I. Rother. (2013) Sucralose, A Synthetic Organochlorine Sweetener: Overview Of Biological Issues. Journal of Toxicology and Environmental Health, Part B 16:7, pages 399-451.
Read now
Read now
Yasushi Yamazoe, Kazumi Ito & Kouichi Yoshinari. (2011) Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order. Drug Metabolism Reviews 43:4, pages 409-439.
Read now
Read now
Michael Riedel, Richard Musil, Florian Seemüller, Ilja Spellmann, Hans-Jürgen Möller & Rebecca Schennach-Wolff. (2010) Safety evaluation of zotepine for the treatment of schizophrenia. Expert Opinion on Drug Safety 9:4, pages 659-666.
Read now
Read now
Shu-Feng Zhou, Bo Wang, Li-Ping Yang & Jun-Ping Liu. (2010) Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metabolism Reviews 42:2, pages 268-354.
Read now
Read now
Shu-Feng Zhou, Jun-Ping Liu & Balram Chowbay. (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 41:2, pages 89-295.
Read now
Read now
Ben Green. (2009) Zotepine: a clinical review. Expert Opinion on Drug Metabolism & Toxicology 5:2, pages 181-186.
Read now
Read now
Maria Gabriella Scordo & Edoardo Spina. (2002) Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 3:2, pages 201-218.
Read now
Read now
Slobodan Rendic. (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 34:1-2, pages 83-448.
Read now
Read now
Articles from other publishers (26)
Samiksha Kukal, Sarita Thakran, Neha Kanojia, Saroj Yadav, Manish Kumar Mishra, Debleena Guin, Pooja Singh & Ritushree Kukreti. (2023) Genic-intergenic polymorphisms of CYP1A genes and their clinical impact. Gene 857, pages 147171.
Crossref
Crossref
Tyler B. Hughes, Na Le Dang, Ayush Kumar, Noah R. Flynn & S. Joshua Swamidass. (2020) Metabolic Forest: Predicting the Diverse Structures of Drug Metabolites. Journal of Chemical Information and Modeling 60:10, pages 4702-4716.
Crossref
Crossref
Habibur Rahman, S.K. Manirul Haque & Masoom Raza Siddiqui. (2020) A Comprehensive Review on Importance and Quantitation of Atypical Antipsychotic Drugs and their Active Metabolites in Commercial Dosage Forms. Current Pharmaceutical Analysis 16:8, pages 989-1019.
Crossref
Crossref
Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Giovanna Cirnigliaro, Isabel Valli & Alfredo Carlo Altamura. (2018) Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clinical Pharmacokinetics 57:12, pages 1493-1528.
Crossref
Crossref
Alexander V. LyubimovEugene G. Hrycay & Stelvio M. Bandiera. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
36
.
Yasushi Yamazoe & Kouichi Yoshinari. (2017) Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 2: Solving substrate interactions of CYP1A2 with non-PAH substrates on the template system. Drug Metabolism and Pharmacokinetics 32:5, pages 229-247.
Crossref
Crossref
Gabriele Cruciani, Aurora Valeri, Laura Goracci, Roberto Maria Pellegrino, Federica Buonerba & Massimo Baroni. (2014) Flavin Monooxygenase Metabolism: Why Medicinal Chemists Should Matter. Journal of Medicinal Chemistry 57:14, pages 6183-6196.
Crossref
Crossref
Takashi Ikeno, Kiyotaka Kugiyama & Hiroto Ito. (2014) Antipsychotic Medication and Risk of QTc Prolongation: Focus on Multiple Medication and Role of Cytochrome P450 Isoforms. Open Journal of Psychiatry 04:04, pages 381-389.
Crossref
Crossref
Ming‐Shang Pai, Szu‐Nian Yang & I‐Shin Shiah. (2012) Rifampin–zotepine interaction reduces effectiveness of antipsychotic drugs in a stable schizophrenia patient. Psychiatry and Clinical Neurosciences 66:6, pages 538-538.
Crossref
Crossref
Pierre Baumann & Christoph Hiemke. 2012. Metabolism of Drugs and Other Xenobiotics. Metabolism of Drugs and Other Xenobiotics
301
329
.
Yoshiyuki Yamaura, Kouichi Yoshinari & Yasushi Yamazoe. (2011) Predicting Oxidation Sites with Order of Occurrence among Multiple Sites for CYP4A-mediated Reactions. Drug Metabolism and Pharmacokinetics 26:4, pages 351-363.
Crossref
Crossref
Noriyuki Koyama & Yasushi Yamazoe. (2011) Development of Two-dimensional Template System for the Prediction of CYP2B6-mediated Reaction Sites. Drug Metabolism and Pharmacokinetics 26:4, pages 309-330.
Crossref
Crossref
M. Shobo, Y. Kondo, H. Yamada, T. Mihara, N. Yamamoto, M. Katsuoka, K. Harada, K. Ni & N. Matsuoka. (2010) Norzotepine, a Major Metabolite of Zotepine, Exerts Atypical Antipsychotic-Like and Antidepressant-Like Actions through Its Potent Inhibition of Norepinephrine Reuptake. Journal of Pharmacology and Experimental Therapeutics 333:3, pages 772-781.
Crossref
Crossref
Eugene G. Hrycay & Stelvio M. Bandiera. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
70
.
Sepuri Asha & Maravajhala Vidyavathi. (2009) Role of Human Liver Microsomes in In Vitro Metabolism of Drugs—A Review. Applied Biochemistry and Biotechnology 160:6, pages 1699-1722.
Crossref
Crossref
Donald J. AbrahamJeffrey M. Brown, Jie Jack Li & Michael W. Sinz. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
161
218
.
Shu-Feng Zhou. (2009) Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. Clinical Pharmacokinetics 48:11, pages 689-723.
Crossref
Crossref
Kazuyoshi Nozaki, Hiroshi Kitagawa, Sumihisa Kimura, Akira Kagayama & Ryuichi Arakawa. (2006) Investigation of the electrochemical oxidation products of zotepine and their fragmentation using on‐line electrochemistry/electrospray ionization mass spectrometry. Journal of Mass Spectrometry 41:5, pages 606-612.
Crossref
Crossref
Mirko S. Faber, Alexander Jetter & Uwe Fuhr. (2005) Assessment of CYP1A2 Activity in Clinical Practice: Why, How, and When?. Basic & Clinical Pharmacology & Toxicology 97:3, pages 125-134.
Crossref
Crossref
E. Tanaka. (2003) Toxicological interactions involving psychiatric drugs and alcohol: an update. Journal of Clinical Pharmacy and Therapeutics 28:2, pages 81-95.
Crossref
Crossref
Toshihiko Kasahara, Masamichi Hashiba, Tsuyoshi Harada & Masakuni Degawa. (2002) Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats. Carcinogenesis 23:3, pages 491-498.
Crossref
Crossref
Marja-Liisa Dahl. (2002) Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics. Clinical Pharmacokinetics 41:7, pages 453-470.
Crossref
Crossref
Jorn Lotsch, Carsten Skarke, Irmgard Tegeder & Gerd Geisslinger. (2002) Drug Interactions with Patient-Controlled Analgesia. Clinical Pharmacokinetics 41:1, pages 31-57.
Crossref
Crossref
Zenzaburo Tozuka, Hayato Kaneko, Toshifumi Shiraga, Yasuyuki Mitani, Akio Kawamura, Akira Kagayama & Anri Aoba. (2002) Strategy for Structure Elucidation of Drug Metabolites Derived from Protonated Molecules and (MS)n Fragmentation of Zotepine, Tiaramide and their Metabolites. Drug Metabolism and Pharmacokinetics 17:4, pages 316-339.
Crossref
Crossref
Maria J. Arranz, David Collier & Robert W. Kerwin. (2001) Pharmacogenetics for the Individualization of Psychiatric Treatment. American Journal of PharmacoGenomics 1:1, pages 3-10.
Crossref
Crossref
Silvio Caccia. (2000) Biotransformation of Post-Clozapine Antipsychotics. Clinical Pharmacokinetics 38:5, pages 393-414.
Crossref
Crossref